COMMUNIQUÉS West-GlobeNewswire
-
Genmab Announces Financial Results for the Nine Months of 2025
06/11/2025 -
Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025
06/11/2025 -
Channel Medsystems Surpasses 5,000 Cerene® Cryotherapy Procedures, Marking Milestone in Women’s Health Innovation
06/11/2025 -
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
06/11/2025 -
LTC ACO Demonstrates Continued Strength, Completing All 2024 Provider Payments
06/11/2025 -
Cytrellis Secures FDA Clearance for Full Body Resurfacing Using Ellacor® Micro-Coring® Technology
06/11/2025 -
Noom Unveils New Diabetes Lifestyle Program and Predictive Glucose Forecasting to Tackle America’s Diabetes Crisis
06/11/2025 -
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
06/11/2025 -
STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion
06/11/2025 -
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
06/11/2025 -
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
06/11/2025 -
Dentsply Sirona Reports Third Quarter 2025 Results
06/11/2025 -
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
06/11/2025 -
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025
06/11/2025 -
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results
06/11/2025 -
Healthcare Minus the Headache: RokketMed, A Solution to Finding the Care That Counts
06/11/2025 -
Raise Craze, a partnership between the MUHC Foundation, The Beat 92.5, and Pink in the City, raised $162,160 for breast cancer care at the MUHC
06/11/2025 -
La campagne Raise Craze, un partenariat entre la Fondation du CUSM, The Beat 92.5 et Pink in the City, recueille 162,160 $ pour les soins contre le cancer du sein au CUSM
06/11/2025 -
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
06/11/2025
Pages